Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Marc Mardoche Fellous"'
Autor:
Virginia Fisher, Lyudmila Bazhenova, Marc Mardoche Fellous, Karen Keating, Emily Castellanos, Andrew Lokker, Jeremy Snider, Jihong Zong, Shivani Nanda, Xiaolong Jiao
Publikováno v:
Targeted oncology, vol 16, iss 3
Targeted Oncology
Targeted Oncology
Background Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. While NTRK gene fusions are predictive of benefit from tropomyosin receptor kinase inhibitors regardless of tumor type, the prognostic
Autor:
Carsten Bokemeyer, Noman Paracha, Ulrik Niels Lassen, Antoine Italiano, Sean D Sullivan, Marisca Marian, Marc Mardoche Fellous, Jesús García-Foncillas
Publikováno v:
Journal of Clinical Oncology. 40:6579-6579
6579 Background: Larotrectinib trials in Tropomyosin Receptor Kinase (TRK) fusion cancer population were single arm trials and therefore limited comparative effectiveness data with larotrectinib are available.MAIC is typically used to balance populat
Autor:
Shivaani Kummar, Lin Shen, Cornelis Martinus van Tilburg, Daniel S.W. Tan, Francois Doz, Raymond S. McDermott, C. Michel Zwaan, Karen N. Keating, Costel Chirila, Ricarda Norenberg, Marc Mardoche Fellous, Nicoletta Brega, Rui-hua Xu, Theodore Willis Laetsch, Alexander E. Drilon, David S. Hong
Publikováno v:
Journal of Clinical Oncology. 40:6563-6563
6563 Background: NTRK gene fusions have been identified as oncogenic drivers in patients (pts) with TRK fusion cancer across multiple solid tumors. Larotrectinib, a highly selective, CNS-active TRK inhibitor has shown high response rates, durable dis
Autor:
Sébastien Perreault, Alexander E. Drilon, Ulrik Niels Lassen, Birgit Geoerger, Karsten Nysom, Ingrid Øra, Igor T. Gavrilovic, Ricarda Norenberg, Marc Mardoche Fellous, Esther A. De La Cuesta, Theodore Willis Laetsch, Francois Doz, Cornelis Martinus van Tilburg
Publikováno v:
Journal of Clinical Oncology. 40:2010-2010
2010 Background: Neurotrophic tyrosine receptor kinase ( NTRK) gene fusions are known oncogenic drivers in a variety of tumor types. Larotrectinib is a highly selective, CNS-active TRK inhibitor that demonstrated an objective response rate (ORR) of 3
Autor:
Leo Mascarenhas, Cornelis Martinus van Tilburg, Francois Doz, C. Michel Zwaan, Catherine M. Albert, Claudia Blattman, Birgit Geoerger, Steven G. DuBois, Noah Federman, Ramamoorthy Nagasubramanian, Alberto S. Pappo, Tanya Carens Watt, Ricarda Norenberg, Marc Mardoche Fellous, Esther A. De La Cuesta, Theodore Willis Laetsch, Rui-hua Xu
Publikováno v:
Journal of Clinical Oncology. 40:10030-10030
10030 Background: Neurotrophic tyrosine receptor kinase ( NTRK) gene fusions are oncogenic drivers in various tumor types across all ages. Larotrectinib is a first-in-class, central nervous system (CNS)-active, highly selective tropomyosin receptor k
Autor:
Catherine M. Albert, Francois P. Doz, Shivaani Kummar, D.S.W. Tan, Theodore W. Laetsch, Hendrik Nogai, Raymond S. McDermott, C.M. van Tilburg, A. Drilon, Stefan S. Bielack, Jordan Berlin, Jessica J. Lin, Makoto Tahara, Ulrik Lassen, David S. Hong, Ricarda Norenberg, R. Xu, Liang Shen, Marc Mardoche Fellous
Publikováno v:
Annals of Oncology. 32:S599-S600
Autor:
Jesús García-Foncillas, John A. Reeves, Ulrik Lassen, Barrett H. Childs, Gilles Vassal, Antoine Italiano, David M. Hyman, Cornelis M. van Tilburg, David S. Hong, Shivani Nanda, Marc Mardoche Fellous, Alexander Drilon, Karen Keating, Shivaani Kummar, Theodore W. Laetsch, Andrew Briggs
Publikováno v:
Italiano, A, Nanda, S, Briggs, A, Garcia-Foncillas, J, Lassen, U, Vassal, G, Kummar, S, van Tilburg, C M, Hong, D S, Laetsch, T W, Keating, K, Reeves, J A, Fellous, M, Childs, B H, Drilon, A & Hyman, D M 2020, ' Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer : An intra-patient comparative analysis ', Cancers, vol. 12, no. 11, 3246, pp. 1-10 . https://doi.org/10.3390/cancers12113246
Cancers, Vol 12, Iss 3246, p 3246 (2020)
Cancers
Volume 12
Issue 11
Cancers, Vol 12, Iss 3246, p 3246 (2020)
Cancers
Volume 12
Issue 11
Randomized controlled basket trials investigating drugs targeting a rare molecular alteration are challenging. Using patients as their own control overcomes some of these challenges. Growth modulation index (GMI) is the ratio of progression-free surv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d024fc92d4edeef52bca35dfcb860cc7
https://curis.ku.dk/ws/files/256216293/cancers_12_03246.pdf
https://curis.ku.dk/ws/files/256216293/cancers_12_03246.pdf
Autor:
Anne Jouinot, Marc Mardoche Fellous, Martin Schlumberger, François Goldwasser, Jennifer Arrondeau, Yoriko De Sanctis, Marcia S. Brose, Gerold Meinhardt, Camille Tlemsani, Olivier Huillard
Publikováno v:
Thyroid
Background: Rates of adverse events with sorafenib were higher in the DECISION trial in radioactive iodine-refractory, advanced differentiated thyroid cancer (DTC) than in trials of sorafenib for other tumor types. One possible explanation is that sa
Autor:
David S. Hong, Marc Mardoche Fellous, Theodore W. Laetsch, A. Drilon, E. De La Cuesta, Afshin Dowlati, Shivaani Kummar, A. Shurshalina, C.M. van Tilburg, K. Guiver, N. Brega
Publikováno v:
Annals of Oncology. 32:S601
Autor:
Karen Keating, Lyudmila Bazhenova, Jihong Zong, John A. Reeves, Amanda Bruno, John Bridgewater, Xiaolong Jiao, Jeran K. Stratford, Mounika Parimi, Atanas Kamburov, Arndt Schmitz, Clare Flach, Marc Mardoche Fellous
Publikováno v:
Cancer Research. 81:394-394
Background: NTRK gene fusions are oncogenic drivers in various tumor types. Overall survival (OS) of patients (pts) with tumors harboring NTRK fusions compared to pts without is unknown, and data on co-occurrence of NTRK fusions with other oncogenic